Gyre Therapeutics (GYRE) Net Income towards Common Stockholders (2010 - 2026)
Gyre Therapeutics (GYRE) reported Net Income towards Common Stockholders of -$8.7 million for Q1 2026, down 422.13% year-over-year from $2.7 million in Q1 2025, and down 404.41% quarter-over-quarter from -$1.7 million in Q4 2025.
Gyre Therapeutics (GYRE) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has 17 years of Net Income towards Common Stockholders data on file, last reported at -$8.7 million in Q1 2026.
- Net Income towards Common Stockholders for Q1 2026 came in at -$8.7 million, down 422.13% year-over-year; the trailing twelve-month figure through Mar 2026 was -$6.4 million (down 187.74% YoY), and the FY2025 annual result was $5.0 million, down 58.4% from the prior year.
- Net Income towards Common Stockholders eased to -$8.7 million in Q1 2026 per GYRE's latest filing, from -$1.7 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at $51.6 million in Q2 2022 and troughed at -$101.0 million in Q4 2023.
- A 5-year average of -$4.8 million and a median of $1.1 million in 2024 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2022 and 2025: Net Income towards Common Stockholders jumped 359.09% in 2022, then sank 1640.4% in 2025.
- A 5-year view of Net Income towards Common Stockholders shows it stood at -$29.9 million in 2022, then tumbled by 237.7% to -$101.0 million in 2023, then jumped by 99.9% to -$99000.0 in 2024, then slumped by 1640.4% to -$1.7 million in 2025, then sank by 404.41% to -$8.7 million in 2026.
- Business Quant data shows GYRE's Net Income towards Common Stockholders at -$8.7 million in Q1 2026, -$1.7 million in Q4 2025, and $3.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | -3.63 Mn |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -56.48 Mn |
| 10 | Gyre Therapeutics | 548.82 Mn | 534.69 Mn | 8.38 Mn | -8.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.69 Mn |
| Dec 31, 2025 | -1.72 Mn |
| Sep 30, 2025 | 3.61 Mn |
| Jun 30, 2025 | 442,000.00 |
| Mar 31, 2025 | 2.70 Mn |
| Dec 31, 2024 | -99,000.00 |
| Sep 30, 2024 | 1.12 Mn |
| Jun 30, 2024 | 3.53 Mn |
| Mar 31, 2024 | 7.53 Mn |
| Dec 31, 2023 | -101.01 Mn |
| Sep 30, 2023 | 3.98 Mn |
| Jun 30, 2023 | 1.85 Mn |
| Mar 31, 2023 | 2.24 Mn |
| Dec 31, 2022 | -29.91 Mn |
| Sep 30, 2022 | -4.88 Mn |
| Jun 30, 2022 | 51.63 Mn |
| Mar 31, 2022 | -14.54 Mn |
| Dec 31, 2021 | -20.31 Mn |
| Sep 30, 2021 | -25.24 Mn |
| Jun 30, 2021 | -19.93 Mn |